Abstract

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.
Lingua originaleEnglish
pagine (da-a)-
Numero di pagine10
RivistaTargeted Oncology
Volume8
Stato di pubblicazionePublished - 2013

Fingerprint

Follistatin
Prostatic Neoplasms
Bone and Bones
Activins
Osteogenesis
Transforming Growth Factor beta
Prostate
Proteins
Therapeutics
Neoplasm Metastasis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)
  • Cancer Research

Cita questo

Follistatin as potential therapeutic target in prostate cancer. /.

In: Targeted Oncology, Vol. 8, 2013, pag. -.

Risultato della ricerca: Article

@article{d0d350fce6694a6e8f9d8235269cbd51,
title = "Follistatin as potential therapeutic target in prostate cancer",
abstract = "Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.",
keywords = "Activin, Bone metastasis.Cancer . Follistatin, Prostate cancer",
author = "Tumminello, {Francesca Maria} and Marilena Crescimanno and Carla Flandina and Gaetano Leto and Marco Giammanco and {Di Majo}, Danila",
year = "2013",
language = "English",
volume = "8",
pages = "--",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",

}

TY - JOUR

T1 - Follistatin as potential therapeutic target in prostate cancer

AU - Tumminello, Francesca Maria

AU - Crescimanno, Marilena

AU - Flandina, Carla

AU - Leto, Gaetano

AU - Giammanco, Marco

AU - Di Majo, Danila

PY - 2013

Y1 - 2013

N2 - Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.

AB - Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.

KW - Activin, Bone metastasis.Cancer . Follistatin, Prostate cancer

UR - http://hdl.handle.net/10447/70447

M3 - Article

VL - 8

SP - -

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

ER -